Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
IndexS&P 500 P/E44.81 EPS (ttm)1.52 Insider Own1.02% Shs Outstand157.64M Perf Week5.79%
Market Cap10.80B Forward P/E31.21 EPS next Y2.19 Insider Trans-5.24% Shs Float156.54M Perf Month16.43%
Income246.65M PEG4.72 EPS next Q0.41 Inst Own97.32% Short Float / Ratio1.85% / 2.57 Perf Quarter-4.63%
Sales1.14B P/S9.44 EPS this Y-6.81% Inst Trans2.02% Short Interest2.90M Perf Half Y-12.90%
Book/sh12.62 P/B5.41 EPS next Y18.01% ROA9.66% Target Price77.87 Perf Year-15.32%
Cash/sh0.94 P/C72.67 EPS next 5Y9.50% ROE13.16% 52W Range51.79 - 89.91 Perf YTD-17.58%
Dividend0.25 P/FCF50.15 EPS past 5Y16.30% ROI9.73% 52W High-24.02% Beta1.25
Dividend %0.37% Quick Ratio3.17 Sales past 5Y12.42% Gross Margin67.78% 52W Low31.90% ATR2.05
Employees3050 Current Ratio4.63 Sales Q/Q2.70% Oper. Margin24.21% RSI (14)66.89 Volatility2.86% 2.91%
OptionableYes Debt/Eq0.28 EPS Q/Q-42.98% Profit Margin21.56% Rel Volume1.09 Prev Close68.05
ShortableYes LT Debt/Eq0.27 EarningsOct 31 BMO Payout18.16% Avg Volume1.13M Price68.31
Recom1.33 SMA209.50% SMA508.15% SMA200-8.73% Volume1,229,200 Change0.38%
Date Action Analyst Rating Change Price Target Change
Dec-07-23Initiated UBS Buy $80
Aug-28-23Initiated William Blair Outperform
Jan-10-23Upgrade Wells Fargo Underweight → Equal Weight $90
Dec-14-22Initiated Deutsche Bank Buy $100
Dec-12-22Upgrade Citigroup Neutral → Buy $81.25 → $100
Dec-07-22Initiated RBC Capital Mkts Sector Perform $89
Aug-25-22Initiated Credit Suisse Outperform $465
Apr-25-22Downgrade Wells Fargo Equal Weight → Underweight $370
Sep-15-21Upgrade KeyBanc Capital Markets Sector Weight → Overweight $600
Mar-08-21Upgrade Stephens Equal-Weight → Overweight $380 → $425
Dec-01-23 01:32AM
Nov-27-23 07:00AM
Nov-13-23 07:00AM
Nov-02-23 07:00AM
Nov-01-23 10:44AM
07:53AM Loading…
Oct-31-23 07:53AM
Oct-25-23 03:42PM
Oct-22-23 10:30AM
Oct-20-23 05:01AM
Oct-19-23 07:00AM
Oct-16-23 07:00AM
07:00AM Loading…
Oct-10-23 07:00AM
Oct-03-23 09:45AM
Sep-28-23 06:00AM
Sep-27-23 07:00AM
Sep-26-23 07:00AM
Sep-25-23 07:00AM
Sep-23-23 09:00AM
Sep-19-23 02:00AM
Sep-18-23 07:32PM
Sep-08-23 11:35AM
Sep-06-23 12:04PM
Aug-28-23 07:32PM
07:00AM Loading…
Aug-24-23 07:00AM
Aug-21-23 01:05PM
Aug-18-23 07:32PM
Aug-15-23 07:00AM
Aug-14-23 07:00AM
Aug-08-23 12:36PM
Aug-05-23 09:49AM
Jul-28-23 05:14PM
Jul-13-23 07:00AM
Jul-10-23 07:00AM
Jun-22-23 02:55PM
Jun-16-23 11:23AM
Jun-01-23 07:00AM
May-29-23 06:47AM
May-25-23 07:00AM
May-18-23 07:00AM
May-16-23 10:45AM
May-12-23 09:07AM
May-10-23 07:00AM
May-03-23 06:30AM
May-02-23 07:00AM
Apr-19-23 07:22PM
Apr-17-23 07:00AM
Apr-13-23 07:00AM
Apr-12-23 07:00AM
Apr-11-23 06:24AM
Apr-05-23 07:00AM
Apr-03-23 07:00AM
Mar-31-23 10:36AM
Mar-27-23 06:45AM
Mar-17-23 07:15AM
Mar-15-23 07:00AM
Mar-10-23 07:00AM
Mar-01-23 07:00AM
Feb-28-23 09:58AM
Feb-26-23 08:39AM
Feb-24-23 08:40AM
Feb-22-23 07:00AM
Feb-14-23 07:00AM
Feb-06-23 02:06AM
Feb-05-23 07:06AM
Feb-02-23 06:30AM
Jan-31-23 07:00AM
Jan-26-23 07:00AM
Jan-24-23 03:25PM
Jan-17-23 07:00AM
Jan-10-23 07:00AM
Jan-07-23 09:09AM
Dec-22-22 11:21AM
Dec-21-22 07:00AM
Dec-19-22 08:43AM
Dec-09-22 05:42PM
Dec-07-22 09:01AM
Dec-05-22 07:00AM
Dec-01-22 07:00AM
Nov-28-22 12:31PM
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nusse RoelandDirectorAug 30Option Exercise22.4032,000716,80060,811Sep 01 04:06 PM
Nusse RoelandDirectorAug 30Sale80.328,939717,95951,872Sep 01 04:06 PM
Kelderman KimPres. Diagnostics & GenomAug 24Option Exercise47.602,10099,96021,225Aug 28 04:19 PM
Kummeth Charles R.Chief Executive OfficerAug 15Option Exercise0.0017,63201,286,944Aug 17 04:14 PM
Kummeth Charles R.Chief Executive OfficerAug 05Option Exercise0.0051,51601,310,282Aug 08 05:31 PM
Hippel JamesCFOAug 05Option Exercise0.0012,876063,896Aug 08 05:29 PM
Kelderman KimPres. Diagnostics & GenomAug 05Option Exercise0.008,060023,264Aug 08 05:28 PM
Kummeth Charles R.Chief Executive OfficerJul 21Sale88.3680,0007,069,0241,258,766Jul 25 05:27 PM
Kummeth Charles R.Chief Executive OfficerJun 30Option Exercise26.65616,67616,434,4151,729,493Jul 05 06:38 PM
Kummeth Charles R.Chief Executive OfficerJun 07Sale83.0032226,7261,112,817Jun 09 04:07 PM
HIGGINS JOHN LDirectorApr 28Option Exercise21.8516,000349,60039,360May 02 04:49 PM
Kummeth Charles R.Chief Executive OfficerJan 04Option Exercise26.65407,36410,856,2511,368,976Jan 06 04:37 PM